Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2B clinical study titled ‘A Phase 2B ...

If over-the-counter antihistamines aren’t effective for you, your doctor may recommend H2 blockers, steroids, biologics, or ...

All the hairs have disappeared from a three-inch long patch on my left arm. The bare patch is half the width of my arm and extends just onto the back of my left hand.

Discover how exercise-induced urticaria can turn your workout into a challenge, affecting those who love to run.

“At 36 weeks, I started feeling itchy hands and feet. I lotioned, ignored it, but it kept getting worse. I kept thinking of ...

The patient has a rash on her cheeks and nose with sparing of the nasolabial folds, in addition to involvement of the dorsal ...

As the colder weather creeps in and people spend more time indoors, viruses like measles are easier to spread, leading ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Basel: Novartis has announced that Rhapsido (remibrutinib) has received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn ...

Investing.com -- Novartis (NYSE:NVS) has received FDA approval for Rhapsido (remibrutinib), the first oral Bruton’s tyrosine kinase inhibitor (BTKi) treatment for chronic spontaneous urticaria (CSU) ...